1-[2-(2-methoxyphenylamino)ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol as a potential anticancer drug

Pharmacology

Volumn 91, Issue 5-6, 2013, Pages 339-345

  Kanno, Takeshi ^a   Tanaka, Akito ^a   Shimizu, Tadashi ^a   Nakano, Takashi ^a   Nishizaki, Tomoyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Anticancer drug; Caspase 4; Malignant mesothelioma; Naftopidil analogue

Indexed keywords

1 [2 (2 METHOXYPHENYLAMINO)EYTHYLAMINO] 3 (NAPHTHALENE 1 YLOXY)PROPAN 2 OL; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 4; EFFECTOR CASPASE; HUHS 1001; HUHS 1002; HUHS 1003; HUHS 1004; HUHS 1005; HUHS 1006; HUHS 1007; HUHS 1008; HUHS 1009; HUHS 1010; HUHS 1011; HUHS 1012; HUHS 1013; HUHS 1014; HUHS 1015; HUHS 1016; HUHS 1017; HUHS 1018; HUHS 1019; HUHS 1020; HUHS 1021; NAFTOPIDIL; UNCLASSIFIED DRUG; 1 [2 (2 METHOXYPHENYLAMINO)ETHYLAMINO] 3 (NAPHTHALENE 1 YLOXY)PROPAN 2 OL; CASPASE 8; CASPASE 9;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY CANCER; LUNG CANCER; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE CANCER; STOMACH CANCER; BLADDER CANCER CELL LINE; DRUG ACTIVITY; DRUG SYNTHESIS; GASTRIC CANCER CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; LUNG CANCER CELL LINE; PROSTATE CANCER CELL LINE; RENAL CANCER CELL LINE;

EID: 84879481638     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000351747     Document Type: Article

References (12)

1. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T: Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn J Pharmacol 1999; 79: 447-454.
2. Hori Y, Ishii K, Kanda H, Iwamoto Y, Nishikawa K, Soga N, Kise H, Arima K, Sugimura Y: Naftopidil, a selective α1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) 2011; 4: 87-96.
3. Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, Sugimura Y: Naftopidil, a selective α-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer 2008; 122: 444-451.
4. Gotoh A, Nagaya H, Kanno T, Nishizaki T: Anti-tumor action of α 1 -adrenoceptor blockers on human bladder, prostate, and renal cancer cells. Pharmacology 2012; 90: 242-246.
5. Masachika E, Kanno T, Nakano T, Gotoh A, Nishizaki T: Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α 1 -adrenoceptor blocking. Anticancer Res 2013; 33: 887-894.
6. Brede M, Philipp M, Knaus A, Muthig V, Hein L: α2-Adrenergic receptor subtypes -novel functions uncovered in gene-targeted mouse models. Biol Cell 2004; 96: 343-348.
7. Kaumann AJ, Molenaar P: Modulation of human cardiac function through 4 β-adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 667-681.
8. Zhong H, Minneman KP: α1-adrenoceptor subtypes. Eur J Pharmacol 1999; 375: 261-276.
9. Nogi Y, Kanno T, Nakano T, Fujita Y, Tabata C, Fukuoka K, Gotoh A, Nishizaki T: AMP converted from intracellularly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis. Cell Physiol Biochem 2012; 30: 61-74.
10. Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y, Manabe T, Yamagishi S, Bando Y, Imaizumi K, Tsujimoto Y, Tohyama M: Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Aβ-induced cell death. J Cell Biol 2004; 165: 347-356.
11. Kim SJ, Zhang Z, Hitomi E, Lee YC, Mukherjee AB: Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL. Hum Mol Genet 2006; 15: 1826-1834.
12. Binet F, Chiasson S, Girard D: Evidence that endoplasmic reticulum (ER) stress and caspase-4 activation occur in human neutrophils. Biochem Biophys Res Commun 2010; 391: 18-23.